Nebulized Budesonide Combined With Systemic Corticosteroid in Acute Severe Asthma

• Status: Unknown status
• Trial end date: 2020-05-20
• Target enrollment: 0
• Participant gender: All

Summary

Our study is a prospective double-blind randomized study performed in the Emergency Department (ED). The objective of our study was to demonstrate the additive effect of high and repeated doses of inhaled budesonide combined with the standard treatment of acute asthma in adult managed in the ED

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Monastir
• Treatments: Bromides; Budesonide; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Hydrocortisone hemisuccinate; Terbutaline

Criteria

Inclusion Criteria:

• acute asthma

• peak expiratory flow (PEF) rate less than 50% of predicted value

• one or more of the following features were present: accessory muscle activity, a heart rate greater than 110 beats/minute, a respiratory rate greater than 25 breaths/minute, a limited ability to speak

• written informed consent obtained

Exclusion Criteria:

• temperature higher than 38°C

• history of cardiac, hepatic, renal, or other medical disease

• pregnant